GENE ONLINE|News &
Opinion
Blog

Market Insight on FDA-approvals: Rise of First-in-class and Regenerative Innovations

by GeneOnline
Share To
Achieving market entry for new drugs has never been more challenging,  especially for non-COVID medications during a time shrouded in COVID-19. Notably, the US FDA has pushed to accelerate the launches of non-COVID medications and has been reviewing more next-generation (Next-Gen) drugs in the last 14 months. Next-Gen drugs, here chiefly describing the first-in-class and regeneration ones which encompass strong clinical benefits and market competitions, are evolving fast year on year.

GO Prime with only $1.49 now

LATEST
Thermo Fisher Scientific to Acquire Sanofi’s Sterile Manufacturing Facility in Ridgefield, New Jersey
2025-07-17
Rethinking Liver Repair: Cellular Insights and Stem Cell Models Tackle Chronic Disease
2025-07-17
University Hospitals Test Methods to Preserve Unused Donor Hearts for Transplantation
2025-07-17
AI Model Reveals Alzheimer’s Drug Reduces Cognitive Decline by 46% in Early-Stage Patients
2025-07-17
Higher Copper Intake Linked to Improved Cognitive Performance in Older Adults
2025-07-17
Danaher India Partners with THSTI to Enhance Biomanufacturing Skills and Infrastructure in India
2025-07-17
Men Over 75 Now Face Highest Suicide Rates According to CDC Data
2025-07-17
EVENT
2025-07-23
BIO Asia–Taiwan 2025
Taipei, Taiwan
2025-08-08
HEALTHY AGEING TECH SHOW
Taipei, Taiwan
2025-08-09
MEDINFO 2025
Taipei, Taiwan
2025-09-03
BIO ASIA PACIFIC 2025
Bangkok, Thailand
2025-09-10
BIOHK 2025
Hong Kong
2025-10-01
Medical Japan 2025
Osaka, Japan
Scroll to Top